Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS)

Inclusion Criteria: * Cerebral infarction except cardiac source of embolism * Onset ≧ 1 week to ≦ 6 months before randomization * Neurological signs persisting ≧ 1 day from onset * Computed tomography (CT) or magnetic resonance imaging (MRI) detection of responsible site * Age ≧ 20 years * Systolic pressure ≦ 180 mmHg; diastolic pressure ≦ 110 mmHg Exclusion Criteria: * Functional outcome at randomization: Modified Rankin Scale = 4, 5 * Previous or planned vascular surgery for cerebral infarction * History of intracranial hemorrhage * History of systemic bleeding, or other history of bleeding diathesis or coagulopathy * Severe complications (renal or hepatic insufficiency, heart failure, hemopathy, etc.) * Pregnant or possibly pregnant women, or nursing mothers * History of sarpogrelate and aspirin sensitivity * Treating malignant tumor or treated within 5 years * Current peptic ulceration